Skip to main content
Clinical Trials/ACTRN12611000450910
ACTRN12611000450910
Completed
Phase 2

Maxi-Analgesic Dose Response Study: A double-blind, placebo-controlled, randomized, parallel group comparison of the effects of diferent paracetamol + ibuprofen combination doses and placebo in participants with pain from removal of 2-4 third molars.

AFT Pharmaceuticals Ltd.0 sites159 target enrollmentStarted: May 3, 2011Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
159

Overview

Brief Summary

All the doses (full dose, half dose and quarter dose) of this fixed dose combination (paracetamol 1000mg + ibuprofen 300mg) provide safe and superior pain relief to placebo in adults for post-operative dental surgery pain relief.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
16 Years to 60 Years (—)
Sex
All

Inclusion Criteria

  • 1\)Provide written informed consent before initiation of any study\-related procedures (including the willingness to stay at the hospital up to 6 hours after the surgery).
  • 2\)Males and females aged at least 16 years and not more than 60 years old on the day of consent.
  • 3\)Undergoing oral surgery for the extraction of 2\-4 impacted 3rd molar teeth, one of which must be mandibular and require bone removal. The molars removed, are either bilateral or ipsilateral.
  • 4\)A resting VAS pain intensity score at baseline (within 6 hours following completion of surgery) of greater than or equal to 50mm on a 100mm VAS scale with 0 ( no pain) and 100 (worst pain imaginable).

Exclusion Criteria

  • Study contra\-indications
  • 1\)Has taken any NSAID or paracetamol within 12 hours prior to the start of surgery other than aspirin less than or equal to 150mg/day.
  • 2\)Subjects who have received any anesthetics from midnight the night prior to surgery, except for lidocaine with epinephrine, nitrous oxide, diazepam (Valium \[Registered Trademark]), methohexitol (Brevital\[Registered Trademark]).
  • 3\)Hypersensitivity to opioids
  • 4\)Known to be pregnant or possibly pregnant.
  • 5\)Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double\-barrier method, or abstinence (should the subject become sexually active, she must agree to use a double\-barrier method of contraception). A woman of childbearing potential is defined as any female who is less than 2 years post\-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g., bilateral tubal ligation, bilateral oophorectomy.
  • 6\)Women of childbearing potential who are unwilling to undergo a urine pregnancy test
  • 7\)Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective.
  • 8\)In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
  • 9\)Currently or in the last 30 days, has been in a clinical trial involving another study drug.

Investigators

Similar Trials